日报更新时间：07-02 06:53
周报更新时间：01-23 11:54
今开价：
最高价：
成交量：
昨收价：
最低价：
最新价：
英文名称：Atossa Genetics
简介：Atossa Genetics Inc.于2009年4月30日在特拉华州注册成立，是一家医疗保健公司，致力于乳腺癌的预防，通过诊断医疗设备和实验室开发的测试推广前体乳腺癌的检测，并通过研究、开发、最终推广前期病变和导管原位癌的治疗
电话：1-800-3513902
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2017-11-14 | Guse (Kyle) | General Counsel | Buy | 1400 | 0.34 |
| 2017-11-14 | Guse (Kyle) | General Counsel | Buy | 8600 | 0.34 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| BlackRock Fund Advisors | 54 | -- | -- | -- | 2019-07-31 |
| Dimensional Fund Advisors LP | 7600 | 0.08% | -1349 | -15.07% | 2019-07-31 |
| Lake Street Risk Retention Group Inc | 26200 | 0.29% | 26200 | -- | 2019-03-31 |
| Bridgeway Capital Management, Inc | 26200 | 0.29% | 26200 | -- | 2019-03-31 |
| Virtu Financial LLC | 36310 | 0.40% | -33593 | -48.06% | 2019-03-31 |
| Geode Capital Management, LLC | 47372 | 0.52% | 15834 | 50.21% | 2019-03-31 |
| Vanguard Group Inc | 69489 | 0.76% | 572 | 0.83% | 2019-03-31 |
| Fidelity Management & Research Company | 80384 | 0.88% | -- | -- | 2019-07-31 |
| Ahrens Investment Partners LLC | 100000 | 1.10% | 100000 | -- | 2019-03-31 |
| Barclays PLC | 7234 | 0.08% | -25150 | -77.66% | 2019-03-31 |
| BARCLAYS CAPITAL Inc | 7184 | 0.08% | -25200 | -77.82% | 2019-03-31 |
| Northern Trust Investments Inc | 2578 | 0.03% | -- | -- | 2019-07-31 |
| Pnc Bank, National Association | 66 | -- | -- | -- | 2019-03-31 |
| PNC Financial Services Group Inc | 66 | -- | -- | -- | 2019-03-31 |
| Mosaic Family Wealth, LLC | 107 | -- | -- | -- | 2019-03-31 |
| Parallax Volatility Advisers, LLC | 209 | -- | 209 | -- | 2019-03-31 |
| BlackRock Asset Management Canada Ltd | 216 | -- | -- | -- | 2019-07-31 |
| BlackRock Inc | 671 | 0.01% | -- | -- | 2019-03-31 |
| Morgan Stanley - Brokerage Accounts | 2383 | 0.03% | 1396 | 141.44% | 2019-03-31 |
| Morgan Stanley Smith Barney LLC | 2383 | 0.03% | 2383 | -- | 2019-03-31 |
| Sabby Management LLC | 502448 | 5.51% | 37409 | 8.04% | 2018-12-31 |
| JANE STREET GROUP, LLC | 22339 | 0.24% | -1253 | -5.31% | 2018-12-31 |
| TWO SIGMA SECURITIES, LLC | 12474 | 0.14% | 12474 | -- | 2018-12-31 |
| Panagora Asset Management Inc | 11255 | 0.12% | -2361 | -17.34% | 2018-12-31 |
| Macquarie Funds Management HK Ltd. | 5700 | 0.06% | 5700 | -- | 2018-12-31 |
| UBS Group AG | 4755 | 0.08% | 4755 | -- | 2018-12-31 |
| Macquarie Group Ltd | 5700 | 0.10% | 5700 | -- | 2018-12-31 |
| Bank of America Corporation | 167 | -- | 167 | -- | 2018-09-30 |
| Wells Fargo & Co | 83 | -- | -- | -- | 2018-09-30 |
| Advisor Group, Inc. | 416 | 0.01% | -- | -- | 2018-09-30 |
| Fifth Third Bancorp | 41 | -- | -- | -- | 2018-09-30 |
| TRUEWEALTH LLC | 45 | -- | -- | -- | 2018-12-31 |
| Invesco Capital Management LLC | 1103 | 0.02% | -- | -- | 2019-01-31 |
| FMR Inc | 27 | -- | 27 | -- | 2018-09-30 |
| Anson Funds Management LP | 108977 | 1.93% | 108977 | -- | 2018-06-30 |
| Vanguard | 465 | 0.01% | -2 | -0.43% | 2018-11-30 |
| Susquehanna International Group, LLP | 24162 | 0.43% | 24162 | -- | 2018-06-30 |
| Susquehanna Financial Group, LLLP | 24162 | 0.43% | 24162 | -- | 2018-06-30 |
| UBS Securities LLC | 9128 | 0.16% | 9128 | -- | 2018-06-30 |
| Deutsche Bank AG | 1107 | 0.02% | 1107 | -- | 2018-06-30 |
| BlackRock Institutional Trust Company NA | 617 | 0.01% | 617 | -- | 2018-06-30 |
| Wells Fargo Advisors, LLC | 83 | -- | -- | -- | 2018-09-30 |
| Guggenheim Funds Investment Advisors LLC | 1260 | 0.02% | -- | -- | 2018-09-14 |
| Intracoastal Capital LLC | 164907 | 0.52% | 164907 | -- | 2018-04-23 |
| Merrill Lynch & Co Inc | 1308 | -- | 1308 | -- | 2017-12-31 |
| Iroquois Capital Management, LLC | 118144 | 0.37% | -2181856 | -94.86% | 2017-12-31 |
| Good Life Advisors, LLC | 20333 | 0.06% | -- | -- | 2017-12-31 |
| Renaissance Technologies Corp | 10824 | 0.03% | -324687 | -96.77% | 2017-12-31 |
| Royal Bank Of Canada | 2 | -- | 2 | -- | 2017-09-30 |
| Morgan Stanley & Co Inc | 178 | -- | 178 | -- | 2017-09-30 |
| Empery Asset Management, LP | 2300000 | 16.40% | 2300000 | -- | 2017-10-26 |
| KCG AMERICAS LLC | 53735 | 0.54% | 3672 | 7.33% | 2017-06-30 |
| Hudson Bay Capital Management LP | 95396 | 0.98% | 26492 | 38.45% | 2017-06-30 |
| Steven C. Quay, M.D., Ph.D. | 4746858 | 3.00% | 8544344 | 0.20% | 1999-11-30 |
| Shu-Chih Chen, Ph.D. | 4268315 | 3.00% | 7682967 | 0.20% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Invesco Wilshire Micro-Cap ETF | -- | -- | -1103 | -100.00% | 2019-02-22 |
| Bridgeway Ultra Small Company Fund | 26200 | 0.29% | 26200 | -- | 2019-03-31 |
| Fidelity | 9613 | 0.11% | -- | -- | 2019-06-30 |
| DFA US Small Cap Portfolio | 5251 | 0.06% | 2351 | 81.07% | 2019-05-31 |
| NT Ext Equity Market Index Fund - L | 2578 | 0.03% | -- | -- | 2019-06-30 |
| DFA Tax Managed US Small Cap Portfolio | 2349 | 0.03% | -- | -- | 2019-06-30 |
| iShares Core S&P US Total Market ETF | 54 | -- | -- | -- | 2019-05-30 |
| iShares Core Balanced ETF Portfolio | 54 | -- | -- | -- | 2019-05-30 |
| iShares Core MSCI AllCntry Wld exCan ETF | 54 | -- | -- | -- | 2019-05-30 |
| iShares Core Growth ETF Portfolio | 54 | -- | -- | -- | 2019-05-30 |
| iShares Core S&P Total US Stock Mkt ETF | 54 | -- | -- | -- | 2019-07-30 |
| DFA US Micro Cap Portfolio | -- | -- | -3700 | -100.00% | 2018-10-31 |
| Vanguard Extended Market Index Fund | 120689 | 1.32% | -- | -- | 2019-06-30 |
| The Vanguard Total Stock Market Index | 465 | 0.01% | -2 | -0.43% | 2017-12-31 |
| iShares Core S&P Total US Stock Mkt | 54 | -- | -- | -- | 2018-09-12 |
| Wilshire Micro-Cap ETF | 1260 | 0.02% | -- | -- | 2018-09-14 |
| DFA US Micro Cap I | 3700 | 0.08% | -- | -- | 2018-07-31 |
| Fidelity Spartan | 13949 | 0.29% | -- | -- | 2018-07-31 |
| Vanguard Extended Market Idx Inv | 33864 | 0.69% | -33864 | -50.00% | 2018-07-31 |
| Fidelity Spartan® Extended Mkt Indx Fd | 80935 | 0.30% | -- | -- | 2015-09-30 |
| iShares Micro-Cap | 60656 | 0.20% | -- | -- | 2015-11-16 |
| The Vanguard - Total Stk Mkt Idx Trust. CF | 7000 | -- | -- | -- | 2015-09-30 |
| Fidelity® NASDAQ Composite Index® Fund | 4348 | -- | -- | -- | 2015-09-30 |
| AXA/Lord Abbett Micro Cap Portfolio | 3682 | -- | -- | -- | 2015-09-30 |
| Fidelity Spartan® Total Market Idx Fund | 789 | -- | -- | -- | 2015-09-30 |
| Vanguard Total Stock Mkt Idx | 295017 | 1.00% | -- | -- | 2015-09-30 |
| Steven C. Quay | Founder of Atossa Genetics, Inc., Sonus Pharmaceuticals, Inc., Nycomed Salutar, Inc. and Salutar, Inc., Steven C. Quay is an entrepreneur and businessperson who has been at the helm of 5 different companies and holds the position of Chairman, President & Chief Executive Officer of Atossa Genetics, Inc. and Chairman & President at National Reference Laboratory For Breast Health, Inc. Dr. Quay is also Member of Society for Laboratory Automation & Screening, Member of American Society for Investigative Pathology, Member of Association for Molecular Pathology and Member of Association for Pathology Informatics, Inc. In his past career Dr. Quay was Chairman & Chief Scientific Officer at Silverleaf Resorts, Inc., Chairman, President & Chief Executive Officer of Atossa Healthcare, Inc. and President & Chief Executive Officer for Sonus Pharmaceuticals, Inc. Steven C. Quay received an undergraduate degree from Western Michigan University and a doctorate from the University of Michigan Medical School. |
|---|---|
| Richard I. Steinhart | Currently, Richard I. Steinhart is Chief Financial Officer & Vice President at BioXcel Therapeutics, Inc. He is also on the board of Atossa Genetics, Inc. and Actinium Pharmaceuticals, Inc. Mr. Steinhart previously was Managing Director at SAE Ventures, Chief Financial Officer of Remedy Pharmaceuticals, Inc., Secretary & Treasurer at STRATA Skin Sciences, Inc., Chief Financial Officer & General Partner at CW Group, Inc., Chief Financial Officer & Vice President for Emisphere Technologies, Inc. and Managing Director at Forest Street Capital, LLC. He received an MBA and an undergraduate degree from Pace University. |
| Gregory L. Weaver | Presently, Gregory L. Weaver holds the position of Chief Financial & Accounting Officer of Eloxx Pharmaceuticals, Inc. He is also on the board of Atossa Genetics, Inc. Mr. Weaver previously was Chief Financial Officer at Poniard Pharmaceuticals, Inc., CFO, Secretary, Treasurer & Senior Vice President at Fibrocell Science, Inc., Chief Financial Officer for Verity Solutions Group, Chief Financial Officer & Senior Vice President at Celsion Corp., Chief Financial Officer for Eloxx Pharmaceuticals, Inc. and Chief Financial Officer for Sevion Therapeutics, Inc. (a subsidiary of Eloxx Pharmaceuticals, Inc.), Global Chief Financial Officer & Executive VP at Oryzon Genomics SA, Chief Financial Officer for ILEX Oncology, Inc., Chief Financial Officer, Secretary & VP at MDRNA, Inc., Chief Financial Officer & Senior Vice President at Sirna Therapeutics, Inc., Chief Financial Officer for Oncology, Inc., Chief Financial Officer at ProMetic Life Sciences, Inc. and Chief Financial Officer at Prism Technologies, Inc. Mr. Weaver received an MBA from Boston College and an undergraduate degree from Trinity University. |
| H. Lawrence Remmel | H. Lawrence Remmel is on the board of Atossa Genetics, Inc. and CytoDel LLC and Partner at Pryor Cashman LLP and Member of New York State Bar Association. He previously occupied the position of Associate of Carter, Ledyard & Milburn LLP and Associate of Reboul, MacMurray, Hewitt, Maynard & Kristol. H. Lawrence Remmel received an undergraduate degree from Princeton University and a graduate degree from Washington & Lee University School of Law. |
| Kyle Guse | Presently, Kyle Guse is CFO, Secretary & Chief Accounting Officer at Atossa Genetics, Inc. In his past career Mr. Guse was Partner at Baker Botts LLP, Partner at McDermott Will & Emery LLP, Partner at Heller Ehrman LLP, Accountant for Deloitte & Touche LLP and Member of California State Bar Association. Mr. Guse received a graduate degree from The Santa Clara University School of Law and an MBA and an undergraduate degree from California State University-Sacramento. |
| Shu Chih Chen | Shu Chih Chen founded Atossa Genetics, Inc. and SC2Q Consulting Co. She is on the board of Atossa Genetics, Inc. Dr. Chen previously was President for SC2Q Consulting Co., President for Ensisheim Partners LLC and Associate Professor at National Yang Ming University. Dr. Chen received a doctorate from Michigan State University and an undergraduate degree from National Yang Ming University. |
| Stephen J. Galli | Stephen J. Galli is on the board of Atossa Genetics, Inc. and Professor at Stanford University School of Medicine. Dr. Galli previously occupied the position of President for American Society for Investigative Pathology and President at Collegium Internationale Allergologicum. He received an undergraduate degree from Harvard College and a doctorate from Harvard Medical School. |
| Janet Rose Rea | Presently, Janet Rose Rea is VP-Regulatory Affairs, Quality & Clinical Affairs at Atossa Genetics, Inc. In her past career Ms. Rea was Assistant Clinical Professor at the University of Washington. She received an undergraduate degree and a graduate degree from the University of Washington. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论